EHA 2024 | The i4MDS consortium and immune monitoring in MDS

No immune monitoring recommendations are incorporated into the current guidelines for the diagnosis and prognosis of myelodysplastic syndromes (MDS) despite it being well-known that the disease is closely related to immune dysfunction. In this joint discussion, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Shahram Kordasti, MD, PhD, King’s College London, London, UK, introduce the International Integrative Innovative Immunology for MDS (i4MDS) initiative, a consortium aimed at advancing the treatment and understanding of MDS. This will be achieved through the standardization of immune monitoring with a basic or expanded panel to generate data that will further the knowledge surrounding the immune dysfunction in MDS, patient stratification, and the optimal timing of anti-inflammatory treatment. Dr Loghavi and Dr Kordasti highlight that this panel should be performed on samples from all patients presenting with unexplained cytopenia. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.